RGNX

REGENXBIO Inc.
CAPPED RATING

Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.

REGENXBIO Inc. (RGNX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.3
EV / EBITDA -3.0
Rev Growth YoY -69.2%
Gross Margin -64.5%
Price Return 3M -32.6%
Price Return 12M -34.1%
Catalyst Signal 0.00
Market Cap $505.2M
TTM Revenue $153.9M
Price / Sales 3.3
ROE -113.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) D+ (1.7) C- (2.1) C (2.4) C+ (2.6) C (2.4)
2026-11-07 B- (3.0) B (3.5) C- (2.0) C- (2.0) C+ (2.7) C+ (2.6)
2026-10-31 B- (3.0) B (3.3) C- (2.1) D+ (1.8) F (0.0) C- (2.1)
2026-10-24 B- (3.0) B (3.3) C- (2.0) D+ (1.7) F (0.0) C- (2.0)
2026-10-17 B- (3.0) B (3.3) C- (2.0) D+ (1.8) F (0.0) C- (2.0)
Page 1 of 8
…